课题基金 / 基金详情

A possible treatment strategy for cardiovascular remodeling by metabolic syndrome-The gene therapy for use of MCP-1 7ND mutated gene-

A possible treatment strategy for cardiovascular remodeling by metabolic syndrome-The gene therapy for use of MCP-1 7ND mutated gene-
代谢综合征引起的心血管重塑的可能治疗策略-利用MCP-1 7ND突变基因的基因治疗-
批准号:
15590781
负责人:
KUWAHARA Fumitaka
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Production of the MCP-17ND:Fc chimera cDNA (7ND) and verification of its dominant-negative activit :At first, we use PCR method to create 7ND cDNA by conjugating the amino-terminal deleted mutant of human MCP-1 and the human immunoglobulin Fc chain. Recombinant 7ND protein was obtained by overexpressing 7ND cDNA in 293 cells and we verified the dominant-negative activity of the recombinant 7ND protein on the MCP-1-induced macrophage production of interferon-gamma. In WKY rats and SD rats, 7ND gene transfer expressed 7ND protein in the muscle and significant elevation of circulating 7ND levels was documented by Elisa, having significant musclular damage at the site of injection (up to 1 g plasmid/kg body weight). However, we could not detect significant expression in circulating 7ND levels in 7ND (1 g/kg)-treated OLEFT rats. One explanation is the difference of the model. Another one is the muscle damage at the transfected site. Because OLEFT rats grow substantial larger than WKY and SD … More rats, the net dose of plasmid solution got much larger, resulting in the myocyte lysis and necrosis. Thus, we are now trying to search more efficient vectors.Evaluation of cardiac remodeling at multiple risk factor model (OLETF Rat) :We used OLETF rats to investigate cardiovascular remodeling in diabetes and hyperlipidemia status. LETF rats were use as controls. In stead of 7ND gene therapy, we used a neutralizing antibody against MCP-1 (NAb) to block MCP-1 activity. NAb or control IgG was administered everyday to OLETF and LETF rats from 30 weeks-old. At 40 weeks of age, we evaluated cardiac hypertrophy, fibrosis and cardiac function. In control OLETF rats had been greater interstitial myocardial fibrosis, especially reparative cardiac fibrosis, and sclerotic change of major vessels, compared with control LETF rats. Preceding cardiac fibrosis, macrophage infiltration and fibroblast proliferation were observed in perivascular space in control OLETF rats. This phenomenon suggested that hyperglycemia is involved in both inflammation changes and tissue damage remodeling. NAb treatment failed to reduce macrophage accumulation and cardiac fibrosis in OLETF rat hearts. We speculated that the inhibitory effects of NAb did not last for 10 weeks Less
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
Kuwahara F, Kai H, et al.: "Hypertensive Myocardial Fibrosis and Diastolic Dysfunction"Hypertension. 43. 1-7 (2004)
Kuwahara F、Kai H 等:“高血压性心肌纤维化和舒张功能障碍”高血压。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tokuda K, Kai H, Kuwahara F et al.: "Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis"Hypertension. 43. 499-503 (2004)
Tokuda K、Kai H、Kuwahara F 等人:“血管紧张素 II 对高血压心肌纤维化的压力独立效应”高血压。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Hypertensive myocardial fibrosis and diastolic dysfunction -Another model of inflammatioin?-
高血压心肌纤维化和舒张功能障碍-另一种炎症模型?-
DOI: --
发表时间: 2004
期刊: Hypertension 43(4)
影响因子: --
作者: [Kuwahara F, Kai H, et al.]
通讯作者: et al.
Tokuda K, Kai H, Kuwahara F et al.: "Sub-depressor dose of angiotensin tipe-1 receptor blocker inhibits t-ansforming grouth factor-beta-mediated privascular fibrosis in hypertensive rat hearts"Journal of Cardiovascular Pharmacology. 42 Suppl 1. S61-S65 (2
Tokuda K、Kai H、Kuwahara F 等人:“亚抑制剂剂量的血管紧张素 Tipe-1 受体阻滞剂抑制高血压大鼠心脏中 t 型生长因子-β 介导的血管前纤维化”《心血管药理学杂志》。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
6
    海外基金